The Compounds That Kill Parasites Living Inside Humans

Blurs.co.uk
13 Min Read
Summarize with AI

From ancient plant remedies to modern pharmaceuticals, antiparasitic medicines exploit the biological weaknesses of organisms that live inside the human body. Some paralyse worms; others disrupt cellular structures, interfere with energy production or damage a parasite’s DNA. Their targets are remarkably varied — because parasites are not all biologically alike.

What counts as a parasite?

The word parasite covers several very different organisms. Helminths are parasitic worms, including roundworms, hookworms, whipworms and tapeworms. Protozoa are microscopic single-celled organisms, including the Plasmodium parasites responsible for malaria and organisms that cause giardiasis, amoebiasis and leishmaniasis. Other parasites, such as lice and mites, live on the body’s surface.

There is therefore no universal “parasite killer”. A compound that is highly effective against one species may have little or no effect on another. Treatment depends on identifying the organism, understanding where it lives and knowing which stage of its life cycle is present.

Albendazole and mebendazole: disrupting worm cells

Albendazole and mebendazole belong to a family of medicines called benzimidazoles. They interfere with tubulin, a protein parasites need to build microtubules — structures involved in maintaining cells and transporting materials within them.

By disrupting microtubule formation, these medicines impair a worm’s ability to absorb and use nutrients. The parasite gradually loses essential cellular functions. These drugs are important treatments for several intestinal worms, including roundworms, hookworms and whipworms. The US Centers for Disease Control and Prevention lists albendazole and mebendazole among the medicines used to treat soil-transmitted helminth infections.

Ivermectin: disabling parasite nerve and muscle activity

Ivermectin is one of the best-known modern antiparasitic medicines. It belongs to the avermectin family and acts on specialised glutamate-gated chloride channels found in many invertebrates. By increasing the movement of chloride ions through these channels, ivermectin disrupts nerve and muscle signalling, often producing paralysis and death in susceptible parasites.

It is used against several parasitic worms and arthropods, including in the treatment and control of onchocerciasis (river blindness) and as part of programmes addressing lymphatic filariasis. Its effectiveness illustrates how a medicine can exploit a biological mechanism that is substantially different in a parasite and its human host.

Praziquantel: attacking parasitic flatworms

Praziquantel is a major treatment for infections caused by parasitic flatworms, particularly schistosomes and several tapeworm species. It alters calcium regulation in susceptible worms, causing intense muscular contraction and damage to the parasite’s outer surface. That damage can also make the worm more vulnerable to the host’s immune response.

Praziquantel is central to the treatment of schistosomiasis, a disease caused by blood flukes whose life cycle involves freshwater snails and human contact with contaminated water.

Triclabendazole: targeting liver flukes

Some parasites occupy specific organs rather than simply living in the intestine. Liver flukes, for example, can inhabit the bile ducts. Triclabendazole is an important treatment for infections caused by Fasciola species, the flukes responsible for fascioliasis. Its particular value is that it is active against important stages of these liver flukes in humans.

Artemisinin: a plant compound that transformed malaria treatment

One of the most remarkable antiparasitic discoveries began with a plant: Artemisia annua, commonly known as sweet wormwood or qinghao. It produces artemisinin, a compound that became the foundation of a new generation of malaria medicines.

Artemisinin has an unusual chemical feature called an endoperoxide bridge. The leading explanation for its action is that parasite chemistry — involving haem and iron as the malaria parasite digests haemoglobin inside red blood cells — helps activate this bridge. The activated compound can generate highly reactive intermediates that damage parasite proteins and other essential molecules. Researchers continue to investigate the precise combination of molecular targets responsible for its rapid action.

Artemisinin and its derivatives act quickly, sharply reducing the number of malaria parasites in the blood. However, they are cleared relatively rapidly from the body and are not generally used alone. Modern treatment relies on artemisinin-based combination therapies (ACTs): an artemisinin derivative rapidly reduces the parasite population, while a longer-lasting partner medicine helps eliminate parasites that remain.

Important derivatives include artesunate, artemether and dihydroartemisinin. The World Health Organization’s malaria guidance describes ACTs as the preferred treatment for uncomplicated Plasmodium falciparum malaria, with different treatment approaches for severe disease.

The discovery of artemisinin

During the 1960s, resistance to established antimalarial medicines was becoming a serious problem. China launched a research programme known as Project 523 in 1967 to search for new treatments. Researcher Tu Youyou and her colleagues examined traditional remedies and investigated Artemisia annua.

Early extracts produced inconsistent results. Tu revisited an ancient Chinese medical text associated with the fourth-century physician Ge Hong, which described preparing qinghao without the high heat used in conventional extraction. The team changed its extraction method and obtained a much more active preparation. The active compound was subsequently isolated and developed into a medicine.

In 2015, Tu Youyou received the Nobel Prize in Physiology or Medicine for discoveries concerning a novel therapy against malaria. The story is not simply that an ancient herbal remedy became a modern drug: traditional knowledge supplied a lead, but isolation, chemical characterisation, testing, clinical research and pharmaceutical manufacturing were essential to turning that lead into reliable treatment. The Nobel Prize profile of Tu Youyou describes the discovery and its significance.

Why absinthe is not an antiparasitic treatment

The connection between artemisinin and wormwood can create confusion. Artemisinin comes from Artemisia annua, whereas traditional absinthe is associated with Artemisia absinthium, or grand wormwood. Absinthe is an alcoholic drink, not a standardised artemisinin medicine. Its thujone content is not a substitute for artemisinin, and drinking it cannot be relied upon to treat malaria or intestinal parasites.

The WHO does not recommend non-pharmaceutical Artemisia plant material for malaria treatment or prevention. Plant preparations vary in composition and cannot provide the controlled dose and proven effectiveness of approved medicines. Inadequate treatment can leave parasites alive and contribute to the wider problem of drug resistance.

Other important antiparasitic compounds

Metronidazole

Metronidazole is active against certain anaerobic organisms and protozoa. It is used in appropriate cases of giardiasis and invasive amoebiasis, among other infections. In susceptible organisms, its activated metabolites can damage DNA and disrupt essential cellular processes. Treatment of amoebiasis may require an additional medicine to clear organisms remaining in the intestine.

Nitazoxanide

Nitazoxanide has activity against certain protozoan parasites, including Giardia and Cryptosporidium in appropriate clinical circumstances. It interferes with metabolic processes that susceptible organisms use to obtain energy.

Diethylcarbamazine

Diethylcarbamazine (DEC) is used against certain filarial worm infections. It has an established role in treating some forms of filariasis and is included in public-health strategies for lymphatic filariasis in settings where it is appropriate.

Atovaquone and proguanil

This combination is used for malaria prevention and treatment in appropriate circumstances. Atovaquone disrupts the parasite’s mitochondrial energy production, while proguanil and its active metabolite interfere with folate-related processes. Together they attack the parasite through more than one pathway.

Why don’t these medicines kill the human host?

The central principle is known as selective toxicity: finding a biological weakness in the parasite that can be targeted without causing unacceptable harm to the patient. Parasites may have receptors humans lack, enzymes with different structures, unusual metabolic pathways or nerve channels that are absent from human cells.

Perfect selectivity is rarely possible. Medicines can still cause side effects, interact with other drugs or be unsuitable for particular patients. The closer a parasite is biologically to humans, the more difficult it can be to find a safe and effective target.

The parasite fights back: drug resistance

Parasites evolve. When a genetic change helps an organism survive exposure to a medicine, surviving parasites may reproduce and pass that advantage on. Over time, resistance can become more common in the parasite population.

Malaria is a prominent example. Partial resistance to artemisinin has been confirmed in parts of the Greater Mekong region and in several African countries. Mutations in the parasite’s Kelch 13 (K13) gene are important markers associated with delayed clearance after treatment. Partial resistance does not automatically mean that every ACT fails: the effectiveness of the partner drug is also crucial. However, resistance makes surveillance and careful treatment policy essential.

Combination therapy can make it harder for a parasite to survive because the medicines attack through different mechanisms. But combinations must be chosen carefully: resistance to a partner drug can undermine the treatment even when the artemisinin component still works.

Why life cycles matter

Many parasites move between organs, hosts or developmental stages. A medicine may work well against an adult worm but not against its eggs or larvae; another may target parasites circulating in the blood but have limited effect on forms in the liver or other tissues. Schistosomes involve freshwater snails in their life cycle, while malaria parasites move between mosquitoes and humans.

Doctors therefore need to consider the parasite species, its location and life-cycle stage, possible resistance, the patient’s age and weight, pregnancy, other health conditions and potential drug interactions. Symptoms such as abdominal pain, diarrhoea, fatigue, weight loss and fever are not enough on their own to identify a parasite. Testing can be essential; for suspected malaria, prompt parasite-based diagnosis and appropriate treatment are particularly important.

An ongoing chemical arms race

Modern medicine has developed an impressive range of antiparasitic compounds. Albendazole and mebendazole disrupt worm-cell structures; ivermectin interferes with nerve and muscle activity; praziquantel damages susceptible flatworms; triclabendazole targets liver flukes; and artemisinin derivatives rapidly attack malaria parasites. Other medicines interfere with DNA, metabolism or energy production.

Yet there is no single chemical solution to parasitic disease. The continuing challenge is to develop new drug targets, improve diagnostics, monitor resistance and use existing medicines appropriately. The objective is not merely to find a substance that kills a parasite, but one that reliably clears the infection while keeping the patient safe — and remains effective as parasites evolve.

Medical note: Antiparasitic medicines are not interchangeable and should not be taken as a general “cleanse”. The correct treatment depends on the organism and the patient. Suspected malaria requires urgent medical assessment; do not delay care or attempt to treat it with alcohol, absinthe or unstandardised plant preparations.

Sources and further reading

Share This Article
Leave a Comment

Leave a Reply